Datavault AI Inc. - Common Stock (DVLT)

Datavault AI (NASDAQ: DVLT) announced a series of executive leadership and board appointments, effective immediately, including Brett Moyer as CEO and president, Kimberly Briskey as board chair, Sri Peruvemba as vice chair, Teri Gallo as chief operating officer, Stanley Mbugua as chief financial officer and Christopher R. Hardt as audit committee chair. Moyer succeeds Nathaniel Bradley, who was removed as CEO and president Nov. 1, 2026, but remains on the board. Mbugua succeeds Moyer as CFO, while Briskey succeeds Moyer as board chair. The company also announced that former executive Sonia Choi is no longer with Datavault and is not authorized to act on its behalf.

Datavault AI Inc. (“Datavault” or the “Company”) (Nasdaq: DVLT) today announced that its Board of Directors has appointed Brett Moyer as Chief Executive Officer and President, Kimberly Briskey as Chair of the Board, Sri Peruvemba as Vice Chair of the Board, Teri Gallo as Chief Operating Officer, Stanley Mbugua as Chief Financial Officer and Christopher R. Hardt as Chair of the Audit Committee, effective immediately. Mr. Moyer succeeds Nathaniel Bradley, who was removed as Chief Executive Officer and President on November 1, 2026. Mr. Bradley remains a member of the Board. Sonia Choi, formerly an executive with the Company, is no longer with the Company, and is not authorized to act on its behalf.

TAMPA, FL / ACCESS Newswire / November 3, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has terminated the Second Amended and Restated letter of intent dated October 19, 2026 ("2nd LOI") with Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.'s ("DHP") wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Inc. ("EOS"), Scilex Holding Company ("Scilex") and HealthBridge Advisors, LLC ("HealthBridge Advisors") for the in-license or acquisition of IP in exchange for Company common stock due to market conditions. DataMEDS does not owe any fees or obligation as a result of the termination.

Anthropic has taken a major step toward becoming a publicly traded company, filing paperwork on Monday for an initial public offering that could rank among the biggest market debuts ever.

Datavault AI (NASDAQ: DVLT), an artificial intelligence platform company providing data monetization, acoustic sciences, credentialing and digital asset management solutions, announced 13 U.S. patent milestones in 2026 for its WiSA(R) wireless audio technology portfolio, comprising three issued patents and 10 additional applications receiving Notices of Allowance from the U.S. Patent and Trademark Office. The issued patents cover audio source localization in multi-speaker systems, techniques for concealing audio transmission interruptions and multi-speaker speech processing. The additional applications address wireless audio transmission, synchronization, device interoperability, error concealment and simplified pairing. The developments strengthen the company’s intellectual property portfolio supporting reliable, low-latency, synchronized multichannel wireless audio.

Three Issued U.S. Patents and 10 Notices of Allowance Strengthen Intellectual Property Protection Across Wireless Audio Transport, Synchronization, Device Interoperability, and Intelligent Audio Processing

Datavault AI (NASDAQ: DVLT) announced that it has entered into a nonbinding letter of intent to acquire a 19.9% equity interest in DataMEDS AI Inc. (NASDAQ: MEDS) in exchange for expanding its existing technology license with the company. The proposed transaction would allow Datavault AI to retain ownership of its underlying intellectual property while potentially generating royalty revenue from commercialization of the licensed technologies. DataMEDS would assume commercialization costs, and Datavault AI would have the right to designate one director to the DataMEDS board following closing. The company believes a fourth-quarter 2026 closing is achievable, subject to due diligence, definitive agreements and customary closing conditions.

Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced that it has entered into a non-binding letter of intent (“LOI”) to acquire a 19.9% equity interest in DataMEDS AI, Inc. (NASDAQ: MEDS) (“DataMEDS”) in consideration of an expansion of its existing technology license with DataMEDS. The proposed transaction is subject to completion of due diligence and negotiation of definitive agreements and will be subject to customary closing conditions for a transaction of this nature.

Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035Customer Acquisition Plan Leverages Existing Relationship with NFL Alumni HealthFinal Guidance issued by FDA Provides Roadmap for Prescription Drug Proprietary Health Lives Here™ App and DelivMeds® SoftwareNetwork of 6,500 Pharmacies to Provide Nationwide Physical Healthcare Outlet

TAMPA, FL / ACCESS Newswire / October 20, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence (artificial intelligence) platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated October 19, 2026, informing DataMEDS that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). In order to regain compliance with the Equity Rule, DataMEDS needed to have a minimum stockholders' equity of $2.5 million.

Utah is introducing independent scrutiny of AI tools being tested through its healthcare regulatory sandbox, requiring participating technologies to undergo outside evaluation before they can be deployed.

Datavault AI (NASDAQ: DVLT), a provider of data monetization, credentialing, digital engagement and real-world asset tokenization technologies, announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its Data Futures Platform patent application. The application describes technology for valuing data assets, generating digital tokens, facilitating marketplace transactions and maintaining transaction verification records, including through blockchain-based systems. The company highlighted the potential relevance of its intellectual property to emerging digital asset markets following the U.S. Securities and Exchange Commission’s Sept. 17, 2026, announcement of a temporary, conditional Innovation Exemption permitting qualifying venues to trade certain tokenized stocks on blockchain infrastructure. Datavault AI intends to evaluate potential commercial applications and partnerships as regulatory frameworks for tokenized securities evolve.

Allowed patent application covers asset valuation, tokenization, transaction verification, and blockchain-enabled marketplaces as a new federal framework opens the door to on-chain trading of tokenized stocks

Datavault AI (NASDAQ: DVLT), an artificial intelligence platform company providing data monetization, credentialing and real-world asset (“RWA”) tokenization, announced the appointment of Jeffrey Tirman to its board of directors, effective Oct. 12, 2026. Tirman was designated by NYIAX Inc. following its recent acquisition by Datavault AI and previously served on the NYIAX board. He brings more than 35 years of international investment management experience spanning corporate restructuring, capital strategy, acquisitions, public listings and cross-border transactions. Tirman currently serves as CEO of Slovenia-based sporting goods manufacturer Elan d.o.o. and is the founder of Abri Capital Ltd., a private family-office investment firm. His appointment adds financial and operational expertise to the board as Datavault AI continues expanding its operations and evaluating opportunities to strengthen its capital structure.

Datavault AI (NASDAQ: DVLT), a provider of data monetization, credentialing, digital engagement and real-world asset (“RWA”) tokenization technologies, announced its participation in the Mass Torts Made Perfect conference, taking place Oct. 13-15, 2026, at the Bellagio in Las Vegas. CEO Nathaniel T. Bradley will deliver a presentation at 3:45 p.m. PT highlighting the company’s potential capabilities in tokenizing tort litigation. Datavault AI executives will also meet with mass tort practitioners, litigation funders and legal industry partners throughout the event to explore opportunities for applying its tokenization technology within the legal sector.